Copyright
©The Author(s) 2015.
World J Gastroenterol. Mar 7, 2015; 21(9): 2746-2753
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2746
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2746
Figure 1 Flow diagram comparing switching to tenofovir disoproxil fumarate monotherapy and continued lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients with a suboptimal response to lamivudine plus adefovir.
LAM: Lamivudine; ADV: Adefovir; TDF: Tenofovir disoproxil fumarate.
- Citation: Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753
- URL: https://www.wjgnet.com/1007-9327/full/v21/i9/2746.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i9.2746